Table 5.: Use of anti-cancer drugs and prevalence of oral mucosal pathology and oral mucositis (N=41).

Anti-Cancer Drug Use of the Anti-Cancer Drug (N) Presence of Mucosal Pathology (%) p-value Presence of Oral Mucositis (%) p-value
Antimetabolites Yes (20)
No (21)
9 (45%)
6 (29%)
0.341 6 (30%)
4 (19%)
0.484
 
Cytotoxic antibiotics Yes (13)
No (28)
10 (77%)
5 (18%)
<0.001 7 (54%)
3 (11%)
0.005
 
Alkylating agent Yes (10)
No (31)
6 (60%)
9 (29%)
0.013 5 (50%)
5 (16%)
0.045
 
Plant alkaloids Yes (9)
No (32)
4 (44%)
11 (34%)
0.701 3 (33%)
7 (22%)
0.662
 
Topoisomerases
inhibitor
Yes (13)
No (28)
7 (54%)
8 (29%)
0.168 4 (31%)
6 (21%)
0.698
 
RTK inhibitor Yes (5)
No (36)
2 (40%)
13 (36%)
1.000 1 (20%)
9 (25%)
1.000

Back to Article